Company intelligence / Profile preview

pHase Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

pHase Pharmaceuticals is developing mRNA therapies delivered via polymer nanoparticles to enable lung cells to produce full-length, functional CFTR protein regardless of CFTR mutations. The company is also exploring applications for gene therapy and gene editing to target other CF-affected organs like the pancreas

Therapeutic areas: Pulmonology
Modalities: mRNA-based drugsNanoparticle
Industry: Biotech

Partnerships

Nanite (mRNA delivery technology development)

Beyond the preview

Go deeper on pHase Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pHase Pharmaceuticals.

Explore the full profile